CD33 28BBz CAR-T cells

CD33 28BBz CAR-T cells are a type of **chimeric antigen receptor (CAR)-T cell therapy** designed to target the **CD33 antigen** on the surface of cells. These engineered T cells incorporate both CD28 and 4-1BB (CD137) costimulatory domains, which, alongside the CD3ζ activation domain, enhance T cell activation, persistence, and anti-leukemia efficacy. The primary application is for the treatment of **acute myeloid leukemia (AML)**, as CD33 is highly expressed on most AML cells. Preclinical data suggest that CD33 28BBz CAR-T cells demonstrate robust anti-tumor effects, improved T cell persistence, and potentially longer-lasting remissions in AML models by reducing cell exhaustion and promoting survival. They are investigated particularly for relapsed or refractory AML, where conventional therapies have limited effectiveness. The technology is generally in early-stage clinical and preclinical development, and these therapies are not yet widely approved or marketed[1][7][5][6].

Other names

CD33 28BBz CAR-T cellsCD-33 28BBz CAR-T cellsCD 33 28BBz CAR-T cellsCD33 28BBz.CAR-T cellsCD-33 28BBz.CAR-T cellsCD 33 28BBz.CAR-T cellsCD33-specific CAR-T cells with CD28 and 4-1BB costimulatory domainsCD-33-specific CAR-T cells with CD28 and 4-1BB costimulatory domainsCD 33-specific CAR-T cells with CD28 and 4-1BB costimulatory domains